Hansa Biopharma — Share Issue/Capital Change 2016

Nov 30, 2016

• PRESS RELEASE - November 30, 2016

Increase of number of shares in Hansa Medical AB (publ)

As previously announced, the general meeting of Hansa Medical AB (publ) has, on November 21, 2016, resolved on a share issue of 2,642,857 ordinary shares. The company's registered share capital and number of outstanding shares and votes have thus increased during November.

As of November 30, 2016, the total number of registered and outstanding shares of Hansa Medical amounts to 35,054,860 of which all are ordinary shares. As of November 30, 2016, the number of votes in Hansa Medical amounts to 35,054,860 and the registered share capital amounts to SEK 35,054,860.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 08:30am CET on November 30, 2016.

For further information, please contact:

Göran Arvidson, CEO, Hansa Medical AB (publ) Mobile: +4670633 3042 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com

About Hansa Medical AB

Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Additional projects focus on development of new antibody modulating enzymes, as well as HBP, a diagnostic biomarker for prediction of severe sepsis at emergency departments that is already introduced on the market. The company is based in Lund, Sweden. Hansa Medical's share (ticker: HMED) is listed on Nasdaq Stockholm.